|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/23 Y-mAbs Therapeutics, Inc. 10-Q 9/30/23 82:8.1M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 2.24M
2: EX-10.1 Material Contract HTML 33K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
12: R1 Document and Entity Information HTML 77K
13: R2 Consolidated Balance Sheets HTML 119K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 36K
15: R4 Consolidated Statements of Net Loss and HTML 101K
Comprehensive Loss
16: R5 Consolidated Statements of Changes in HTML 92K
Stockholders' Equity
17: R6 Consolidated Statements of Cash Flows HTML 87K
18: R7 Organization and Description of Business HTML 26K
19: R8 Basis of Presentation HTML 31K
20: R9 Summary of Significant Accounting Policies HTML 88K
21: R10 Product Revenue, Net HTML 60K
22: R11 Net Loss Per Share HTML 51K
23: R12 Inventories HTML 57K
24: R13 Intangible Assets, Net HTML 26K
25: R14 Accrued Liabilities HTML 43K
26: R15 License Agreements and Commitments HTML 157K
27: R16 Stockholders' Equity HTML 34K
28: R17 Share-Based Compensation HTML 98K
29: R18 Income Taxes HTML 30K
30: R19 Other Benefits HTML 25K
31: R20 Restructuring Charge HTML 27K
32: R21 Summary of Significant Accounting Policies HTML 113K
(Policies)
33: R22 Summary of Significant Accounting Policies HTML 61K
(Tables)
34: R23 Product Revenue, Net (Tables) HTML 51K
35: R24 Net Loss Per Share (Tables) HTML 49K
36: R25 Inventories (Tables) HTML 55K
37: R26 Accrued Liabilities (Tables) HTML 43K
38: R27 License Agreements and Commitments (Tables) HTML 137K
39: R28 Share-Based Compensation (Tables) HTML 86K
40: R29 BASIS OF PRESENTATION - Accumulated deficit HTML 26K
(Details)
41: R30 BASIS OF PRESENTATION - Cash and cash equivalents HTML 26K
(Details)
42: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 31K
Concentration of Credit Risk (Details)
43: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K
Inventories (Details)
44: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 41K
Value Measurements (Details)
45: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 24K
Operating Leases (Details)
46: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 33K
Revenue Recognition - Product revenue, net
(Details)
47: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 58K
Revenue Recognition - License revenue (Details)
48: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K
Segment Information (Details)
49: R38 PRODUCT REVENUE, NET - Product revenue and HTML 52K
receivables (Details)
50: R39 PRODUCT REVENUE, NET - Reserves for discounts and HTML 66K
allowances (Details)
51: R40 PRODUCT REVENUE, NET - Concentrations (Details) HTML 55K
52: R41 NET LOSS PER SHARE - Basic and diluted (Details) HTML 50K
53: R42 NET LOSS PER SHARE - Anti-dilutive securities HTML 25K
(Details)
54: R43 Inventories (Details) HTML 44K
55: R44 Intangible Assets, Net (Details) HTML 44K
56: R45 Accrued Liabilities (Details) HTML 36K
57: R46 LICENSE AGREEMENTS AND COMMITMENTS - MSK License HTML 29K
Agreement (Details)
58: R47 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 36K
Agreement (Details)
59: R48 LICENSE AGREEMENTS AND COMMITMENTS - Summary of HTML 63K
Significant Agreements and Commitments (Details)
60: R49 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 44K
agreements (Details)
61: R50 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 33K
(Details)
62: R51 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 40K
maturities (Details)
63: R52 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 27K
and discount rate (Details)
64: R53 LICENSE AGREEMENTS AND COMMITMENTS - Severance HTML 32K
Related Benefits (Details)
65: R54 LICENSE AGREEMENTS AND COMMITMENTS - Legal matters HTML 28K
(Details)
66: R55 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 42K
Preferred Stock (Details)
67: R56 STOCKHOLDERS' EQUITY - Stock Grant Agreements with HTML 59K
Non Employees (Details)
68: R57 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 36K
69: R58 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 55K
70: R59 SHARE-BASED COMPENSATION - Stock-based HTML 45K
compensation expense - Options (Details)
71: R60 SHARE-BASED COMPENSATION - Stock option activity HTML 62K
(Details)
72: R61 SHARE-BASED COMPENSATION - Stock option grants HTML 60K
(Details)
73: R62 SHARE-BASED COMPENSATION - Stock option HTML 36K
unrecognized compensation (Details)
74: R63 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 74K
Activity (Details)
75: R64 INCOME TAXES - Loss before income taxes (Details) HTML 36K
76: R65 Other Benefits (Details) HTML 31K
77: R66 Restructuring Charge (Details) HTML 40K
80: XML IDEA XML File -- Filing Summary XML 145K
78: XML XBRL Instance -- ymab-20230930x10q_htm XML 1.77M
79: EXCEL IDEA Workbook of Financial Report Info XLSX 142K
8: EX-101.CAL XBRL Calculations -- ymab-20230930_cal XML 127K
9: EX-101.DEF XBRL Definitions -- ymab-20230930_def XML 617K
10: EX-101.LAB XBRL Labels -- ymab-20230930_lab XML 1.18M
11: EX-101.PRE XBRL Presentations -- ymab-20230930_pre XML 944K
7: EX-101.SCH XBRL Schema -- ymab-20230930 XSD 184K
81: JSON XBRL Instance as JSON Data -- MetaLinks 407± 625K
82: ZIP XBRL Zipped Folder -- 0001558370-23-018827-xbrl Zip 459K
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Rossi certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Y-mAbs Therapeutics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| | ||
Dated: November 13, 2023 | By: | /s/ Michael Rossi | |
| | Name: | |
| | Title: | President, Chief Executive Officer |
| | | (Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/13/23 | None on these Dates | ||
| For Period end: | 9/30/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/18/23 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 10/12/23 13:454K Toppan Merrill/FA 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA |